Introduction
============

Soil transmitted helminthiasis is caused by infections with the nematode worm *Ascaris lumbricoides*, the hookworms *Necator americanus* and *Ancylostoma duodenale*, and *Trichuris trichiura*. An estimated 5.3 billion of people are at risk, while 1.5 billion are infected with at least one of the soil transmitted helminths.[@ref1] Despite a global decline in infections, prevalence remains high in Asia, followed by sub-Saharan Africa and Latin America.[@ref1] *A lumbricoides* and *T trichiura* infections particularly affect preschool and school aged children, while hookworm infections are more prevalent in adults. Infected people predominantly live in poor conditions in the least developed countries, where households lack adequate facilities and clean water. Morbidity correlates with the number of worms harboured by infected individuals. While light infections commonly remain asymptomatic, moderate and heavy infections cause severe morbidity,[@ref2] including growth stunting, intellectual impairment, cognitive and educational deficits, malnutrition, and iron deficiency anaemia.[@ref3] In 2015, the global burden of infections with soil transmitted helminths was estimated at 3.4 million disability adjusted life years (DALYs).[@ref4]

The goal of the World Health Organization (WHO) is to reduce the prevalence of moderate and heavy infections with soil transmitted helminths in preschool and school aged children to below 1% by 2020.[@ref5] [@ref6] [@ref7] To achieve this goal, school aged children in endemic areas are regularly treated in so called preventive chemotherapy programmes.[@ref5] [@ref6] [@ref8] In 2015, about 573 million children received preventive chemotherapy against soil transmitted helminths, corresponding to a global coverage of 59.5%.[@ref9] The ultimate target is to cover at least 75% of school aged children in need of treatment.[@ref6] Albendazole, mebendazole, levamisole, and pyrantel pamoate are currently on the WHO list of essential medicines for the treatment of such infections,[@ref6] [@ref7] while the two benzimidazoles---albendazole and mebendazole---are the most widely used drugs in preventive chemotherapy programmes.[@ref8]

The efficacy of albendazole, mebendazole, and pyrantel pamoate has been assessed in a systematic review for different dose regimens[@ref10] and by means of meta-analysis of randomised controlled trials for single doses.[@ref11] Albendazole, mebendazole, and pyrantel pamoate had high efficacy against *A lumbricoides* in terms of cure rates. Only albendazole was found to be efficacious in single dose regimen against hookworm (cure rate 72%). Both albendazole and mebendazole had unsatisfactory results against *T trichiura* at single doses with cure rates of 28% and 36%, respectively.[@ref11] Of concern, recent results from randomised trials on Pemba Island (Tanzania) showed even lower cure rates for albendazole (2.6%) and mebendazole (11.8%) against *T trichiura*.[@ref12]

We updated the findings from the two systematic reviews,[@ref10] [@ref11] including new evidence and applying network meta-analysis methods. The comparison of intervention effects among randomised controlled trials with conventional meta-analysis is limited by the constraint that only drugs tested in the same study can be compared.[@ref11] In contrast, network meta-analysis draws strength from direct and indirect comparisons through common comparators (such as placebo). Furthermore, multiple drugs can be compared and ranked.[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] In addition, for the first time we meta-analysed egg reduction rates, the standard key parameter for drug efficacy.[@ref18] Our analysis provides current evidence on anthelmintic drug efficacy, which is of considerable relevance to policy makers as they call for an adaptation of current treatment guidelines.

Methods
=======

Search strategy and selection criteria
--------------------------------------

This review and meta-analysis is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension statement for network meta-analysis.[@ref19] The study protocol is provided in appendix 1. We conducted an electronic literature search on PubMed, ISI Web of Science, Embase, ScienceDirect, the Cochrane Central Register of Clinical trials, and the WHO library database. All studies from 1960 until 31 December 2016 were considered. The search was not restricted to any language, and, in case of non-English articles, native speakers were consulted for full text translations. The triple MeSH search terms included "albendazole", "mebendazole", "levamisole", and "pyrantel pamoate" combined with either "trial", "study", or "case report" and "*Ascaris lumbricoides*", "ascariasis", "hookworm", "*Ancylostoma duodenale*", "*Necator americanus*", "*Trichuris trichiura*", "trichuriasis", or "soil-transmitted helminths" (table A, appendix 1).

To be eligible for inclusion, studies had to be level 1 randomised controlled trials (<https://www.elsevier.com/__data/promis_misc/Levels_of_Evidence.pdf>) that reported the efficacy against *A lumbricoides*, hookworm, and *T trichiura* in terms of cure rates, egg reduction rates, or both. For this review we selected randomised controlled trials that included at least one treatment arm of the currently recommended[@ref7] [@ref10] [@ref20] single dose regimens of albendazole (400 mg), mebendazole (500 mg), levamisole (80 mg or 2.5 mg/kg), or pyrantel pamoate (10 mg/kg). There were no age restrictions. Studies were excluded if they were not randomised controlled trials, used different drug regimens (such as multiple doses or different drug regimens), or combined different drugs or if the follow-up was shorter than one or longer than six weeks.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community. We did not evaluate whether the studies included in the review had any patient involvement.

Data extraction and assessment of risk bias
-------------------------------------------

From each eligible randomised controlled trial we extracted number of infected participants at baseline, number of cured participants at follow-up, mean number of eggs at baseline, mean number of eggs at follow-up, percentage of egg reduction, measure of central tendency (arithmetic, geometric, or not described), information on the number of treatment arms, number of eligible treatment arms, year of publication, country, diagnostic method, age range, and time between treatment and follow-up.

Two independent reviewers (WM and JK) screened titles and abstracts for potential studies. When articles met the inclusion criteria, the entire manuscripts were scrutinised, and, for eligible trials, the data were extracted independently by the same reviewers. All included trials were assessed for quality by two different methods: that described by Jadad and colleagues,[@ref21] with scores ranging between 1 (lowest level) and 5 (highest level), and according to the Cochrane Collaboration Handbook (table A in appendix 2).[@ref22] The latter criteria assess studies for risk of bias in six different domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. Each domain is categorised into low, high, or unclear risk of bias. In case of discrepancies over extraction of data or scoring of the study quality, a third person (CS) was involved and the results discussed until consensus was reached.

Data synthesis and statistical analysis
---------------------------------------

The advantage of a network meta-analysis is the simultaneous combination of direct and indirect estimates of the treatment effect in one analysis. In data from clinical trials with direct estimates for drug A *v* B and other trials comparing A *v* C, we can estimate the relative treatment effect for B *v* C and all three drugs can be ranked.[@ref13] [@ref23] To illustrate the network geometry, we have provided a separate plot for cure rates and egg reduction rates (fig 1[](#f1){ref-type="fig"}).[@ref23] For the network meta-analysis of the cure rates, we used a method proposed by Kessels and colleagues.[@ref24] The method consists of rebuilding the original datasets based on sample sizes and case numbers retrieved from the publications. All datasets from studies with one, two, or more treatment arms were then pooled, and mixed logistic regression models were applied to the final pooled dataset. With this method even studies with only one eligible treatment arm can be included. The models included treatment as a fixed factor and random effects for studies and for treatment arms within studies. To mimic meta-regression analysis, we additionally included the respective regressor variable and its interactions with the treatments.

![**Fig 1** Flowchart and network showing procedure for identification of relevant publications. Circular nodes show each treatment with circle size indicating amount of respective evidence and numbers in brackets indicating number of pooled studies with only one eligible treatment arm. Weight of line and number on line indicate number of direct treatment comparisons within same study](mosw037871.f1){#f1}

We recorded all egg reduction rates directly from the articles and used mixed linear models for the meta-analysis of these rates. These models included the fixed factors treatment, infection intensity (dichotomised as above versus below median of baseline egg counts), measure of central tendency (arithmetic mean, geometric mean, or not described), and random effects for studies. We considered baseline infection intensity to increase precision and to achieve approximate normality of regression residuals.

Table 1[](#tbl1){ref-type="table"} shows the average cure rates and egg reduction rates per treatment derived from the underlying regression models as marginal estimates. We presented one sided 95% confidence intervals if the limits of the respective two sided interval exceeded 0 or 100%. We carried out one to one comparisons of cure rates and egg reduction rates by looking at the differences of the respective regression coefficients (fig 2[](#f2){ref-type="fig"}). In the case of cure rates we used exponentiation to convert these differences into odds ratios. We also conducted a simple, pairwise meta-analysis of cure rates for the one to one comparison using the command metan in Stata. Table C in appendix 2 and fig B in appendix 3 show the respective summary odd ratios, I^2^, and τ^2^ statistics, where they are compared with the corresponding odd ratio estimates from network meta-analysis.

###### 

Average cure rates (%) and egg reduction rates (%) of albendazole, mebendazole, levamisole, and pyrantel pamoate against *A lumbricoides*, hookworm, and *T trichiura* based on network meta-analysis

  Treatment              Cure rates          Egg reduction rates                        
  ---------------------- ------------ ------ --------------------------- -- ---- ------ ----------------------------
  ***A lumbricoides***                                                                  
  Placebo                14           842    12.7 (6.7 to 22.7)             9    525    20.7 (14.7 to 26.7)
  Albendazole            34           3360   95.7\*\*\* (93.2 to 97.3)      26   2854   98.5\*\*\* (94.9 to 100.0)
  Mebendazole            13           1548   96.2\*\*\* (92.3 to 98.1)      13   1529   98.0\*\*\* (94.0 to 100.0)
  Levamisole             2            149    97.3\*\*\* (84.2 to 99.6)      1    125    96.4\*\*\* (82.3 to 100.0)
  Pyrantel pamoate       11           1374   92.6\*\*\* (85.6 to 96.3)      6    284    94.3\*\*\* (88.3 to 100.0)
  Total                  44           7273    ---                           33   5137    ---
  **Hookworm**                                                                          
  Placebo                18           1309   15.2 (9.3 to 23.9)             14   1046   16.2 (5.3 to 27.1)
  Albendazole            30           3104   79.5\*\*\* (71.5 to 85.6)      26   2839   89.6\*\*\* (81.9 to 97.3)
  Mebendazole            14           2305   32.5^\*^ (20.8 to 46.9)        14   2263   61.0\*\*\* (52.0 to 69.9)
  Levamisole             2            230    10.3 (2.4 to 35.2)             1    202    61.8^\*^ (30.3 to 93.3)
  Pyrantel pamoate       7            230    49.8\*\* (29.5 to 70.1)        5    144    71.9\*\*\* (54.7 to 89.0)
  Total                  38           7178    ---                           34   6494    ---
  ***T trichiura***                                                                     
  Placebo                11           1417   8.6 (4.1 to 17.1)              28   1049   19.2 (6.9 to 31.4)
  Albendazole            33           4432   30.7\*\*\* (21.0 to 42.5)      29   3407   49.9\*\*\* (39.0 to 60.6)
  Mebendazole            13           2514   42.1\*\*\* (25.9 to 60.2)      14   2507   66.0\*\*\* (54.6 to 77.3)
  Levamisole             2            203    29.5 (6.1 to 72.9)             1    197    28.3 (6.7 to 49.8)
  Pyrantel pamoate       6            275    20.2 (7.3 to 44.7)             4    158    47.5\*\* (25.5 to 69.6)
  Total                  38           8841    ---                           33   7318    ---

\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 for comparison with placebo.

![**Fig 2** Drug comparison based on network meta-analysis. Odds ratios for one to one comparisons of cure rates and difference for one to one comparisons of egg reduction rates are based on network meta-analysis for each drug and infection (\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001)](mosw037871.f2){#f2}

In a second stage, we stratified analysis for cure rates and egg reduction rates according to continent, place of the study, sensitivity of diagnostic method, quality of the study, length of follow-up, intensity of infection at baseline, and year of publication (see tables D-J in appendix 2). By letting the treatment interact in the mixed regression model separately with study size and year, we estimated cure rates and egg reduction rates for small (n=30) and large (n=300; table K in appendix 2) studies and for years 1995 and 2015 (table L in appendix 2), to examine publication bias and evaluate the potential trends of efficacy over time.

We assessed the consistency between estimated odd ratios from direct and indirect comparisons by adding indicator variables for the two respective parallel treatments to the mixed logistic regression models. The difference of their regression coefficients was exponentiated to obtain the ratio between the odds ratio from direct and the odds ratio from indirect comparison (referred to as ratio of odds ratios). The two variables were obtained as the product of the respective treatment indicator variable and the indicator variable for studies that compared both treatments directly. The ratio of odds ratios (and 95% confidence intervals) measuring inconsistency between direct and indirect estimates are shown in appendix 3 (fig C). All analyses were done with STATA version 14.0 (StataCorp, College Station, TX, USA).

Results
=======

Characteristics of included studies and bias assessment
-------------------------------------------------------

We identified 301 potential studies of albendazole, mebendazole, levamisole, and pyrantel pamoate for treating soil transmitted helminth infections (fig 1[](#f1){ref-type="fig"}). From these, we excluded 245: 82 were not randomised, 87 used a different dose regimen, 37 had follow-up longer than six weeks, 23 used only drug combinations, and data were not extractable from 16 (table B in appendix 2). From the 56 remaining studies, one included only egg reduction rates, while 10 did not report egg reduction rates. A total of 44 studies had data on cure rates against *A lumbricoides*, and 38 presented data on hookworm and *T trichiura*. For the analysis of egg reduction rates we included 34 studies for hookworm and 33 for *A lumbricoides* and *T trichiura*. Studies including treatments consisting of placebo and albendazole and albendazole and mebendazole were most common. The inconsistency plot showed considerable differences between odd ratios of cure from direct and indirect comparisons for some of the drug pairs (fig C in appendix 3), but none of these differences reached significance.

The percentages of studies in the lowest categories for risk of bias were 41.1% for random sequence generation, 30.4% for allocation concealment, and 51.8% for incomplete outcome data. The percentage of studies in the highest category for risk of bias was largest for blinding of participants and personnel (25.6%). The category of unclear risk was largest in all criteria other than "incomplete outcome data." This was especially pronounced among studies published before the year 2000 (table M in appendix 2).

Drug efficacy against *A lumbricoides*
--------------------------------------

We evaluated 44 studies with an average Jadad score of 2.5 and a total of 7273 participants positive for *A lumbricoides* (table N in appendix 2 gives detailed numbers) to evaluate the effect of the four anthelmintic drugs against *A lumbricoides* (fig 1[](#f1){ref-type="fig"}). Pooled estimates were based on 19 studies with only one treatment,[@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] 22 studies with two treatments,[@ref12] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] and three studies with three eligible treatments.[@ref64] [@ref65] [@ref66]

The four anthelmintic drugs investigated showed highly significant superiority (all P\<0.001) over placebo (the average cure rate with placebo was 12.7% (95% confidence interval 6.7% to 22.7%; table 1[](#tbl1){ref-type="table"}). Estimated average cure rates were 95.7% (93.2% to 97.3%) for albendazole, 96.2% (92.3% to 98.1%) for mebendazole, 97.3% (84.2% to 99.6%) for levamisole, and 92.6% (85.6% to 96.3%) for pyrantel pamoate. There were no significant differences among the four treatments in the one to one comparison (fig 2[](#f2){ref-type="fig"}).

Thirty three studies reported egg reduction rates[@ref12] [@ref25] [@ref26] [@ref29] [@ref31] [@ref32] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref51] [@ref52] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref64] [@ref66] [@ref67] (fig 3[](#f3){ref-type="fig"}). All treatment arms showed significantly higher rates (P\<0.001) than placebo (20.7%, 95% confidence interval 14.7% to 26.7%; table 1[](#tbl1){ref-type="table"}), while there were no significant differences between the rates with the four treatments (fig 2[](#f2){ref-type="fig"}). The highest estimated egg reduction rate (98.5%, 94.9% to 100.0%) was for albendazole, followed by 98.0% (94.0 to 100.0) for mebendazole, 96.4% (82.3 to 100.0) for levamisole, and 94.3% (88.3 to 100.0) for pyrantel pamoate.

![**Fig 3** Egg reduction rates for albendazole, mebendazole, levamisole, and pyrantel pamoate. Median, third quarter (white bar), second quarter (shaded bar), and individual study specific rates (solid circles) for each drug against *A lumbricoides*, hookworm, and *T trichiura*. Negative values of rates were set to zero in this figure](mosw037871.f3){#f3}

Drug efficacy against hookworm
------------------------------

For estimating the drug efficacy against hookworm, we looked at data from 7178 individuals from 38 studies (table 1[](#tbl1){ref-type="table"}; table N in appendix 2) with an average Jadad score of 2.8. Pooled estimates included 12 studies with one treatment,[@ref25] [@ref26] [@ref30] [@ref31] [@ref32] [@ref34] [@ref36] [@ref38] [@ref42] [@ref43] [@ref68] 21 studies with two treatments,[@ref12] [@ref43] [@ref44] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref62] [@ref63] [@ref68] [@ref69] [@ref70] and five studies with three treatments.[@ref64] [@ref65] [@ref66] [@ref71] [@ref72]

The cure rate was 15.2% (95% confidence interval 9.3% to 23.9%) for placebo (table 1[](#tbl1){ref-type="table"}). The rate with levamisole (10.3%, 2.4% to 35.2%) did not differ significantly from the placebo rate, but was significantly higher with albendazole (79.5%, 71.5% to 85.6%; P\<0.001), mebendazole (32.5%, 20.8% to 46.9%; P=0.011), and pyrantel pamoate (49.8%, 29.5% to 70.1%; P=0.001). The one to one comparison of cure rates showed a strongly increased odds of cure after the administration of albendazole compared with mebendazole (P\<0.001), levamisole (P\<0.001), and pyrantel pamoate (P=0.005, fig 2[](#f2){ref-type="fig"}). The odds for levamisole were significantly lower than the odds for pyrantel pamoate (P=0.016).

We used data from 34 studies[@ref12] [@ref25] [@ref26] [@ref30] [@ref31] [@ref32] [@ref34] [@ref36] [@ref38] [@ref43] [@ref44] [@ref46] [@ref47] [@ref48] [@ref49] [@ref51] [@ref52] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref62] [@ref64] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] [@ref72] (fig 3[](#f3){ref-type="fig"}) to determine an egg reduction rate of 16.2% (95% confidence interval 5.3% to 27.1%) for placebo, which was significantly lower than the rates for all active treatments (table 1[](#tbl1){ref-type="table"}). Albendazole had the highest average rate of 89.6% (81.9% to 97.3%), followed by pyrantel pamoate (71.9%, 54.7% to 89.0%), levamisole (61.8%, 30.3% to 93.3%), and mebendazole (61.0%, 52.0% to 69.9%). The one to one comparison showed a significant difference between albendazole and mebendazole (P\<0.001, fig 2[](#f2){ref-type="fig"}).

Drug efficacy against *T trichiura*
-----------------------------------

We used data from 38 studies (average Jadad score of 2.6), including 8841 participants positive for *T trichiura* (table 1[](#tbl1){ref-type="table"}; table N in appendix 2) for analysis of cure rates of the four drugs against *T trichiura*. Pooled estimates were based on 16 trials with one treatment,[@ref25] [@ref26] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref35] [@ref36] [@ref37] [@ref38] [@ref40] [@ref42] [@ref43] [@ref73] [@ref74] 19 studies including two treatments,[@ref12] [@ref43] [@ref44] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref62] [@ref63] [@ref75] and three studies with three treatments.[@ref64] [@ref65] [@ref66]

The cure rate was 8.6% (95% confidence interval 4.1% to 17.1%) with placebo, which was not significantly different from the rates with levamisole (29.5%, 6.1% to 72.9%) and pyrantel pamoate (20.2%, 7.3% to 44.7%; table 1[](#tbl1){ref-type="table"}). Albendazole and mebendazole showed significantly higher efficacy than placebo, with estimated cure rates of 30.7% (21.0% to 42.5%; P\<0.001) and 42.1% (25.9% to 60.2%; P\<0.001), respectively. We found no significant differences among the rates of the four treatments comparing them one to one (fig 2[](#f2){ref-type="fig"}).

We used 33 studies for analysis of the egg reduction rates[@ref12] [@ref25] [@ref26] [@ref29] [@ref31] [@ref35] [@ref36] [@ref37] [@ref38] [@ref43] [@ref44] [@ref46] [@ref47] [@ref48] [@ref49] [@ref51] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref62] [@ref63] [@ref64] [@ref66] [@ref67] [@ref73] [@ref74] [@ref75] [@ref76] (fig 3[](#f3){ref-type="fig"}). The average rate was 19.2% (95% confidence interval 6.9% to 31.4%) for placebo, which was significantly lower than the rates for albendazole (P\<0.002), mebendazole (P\<0.001), and pyrantel pamoate (P=0.008) but comparable with the rate for levamisole (28.3%, 6.7% to 49.8%; table 1[](#tbl1){ref-type="table"}). The highest rate of 66.0% (54.6% to 77.3%) was estimated for mebendazole, which was significantly higher than the rate for albendazole (49.9%, 39.0% to 60.6%; P\<0.001) and levamisole in the one to one comparison (fig 2[](#f2){ref-type="fig"}). For pyrantel pamoate the rate was 47.5% (25.5% to 69.6%).

Stratification by publication year (before *v* after 2000), resulted in a significantly reduced cure rate for albendazole (44.9% (95% confidence interval 29.4% to 61.5%) *v* 23.7% (14.2% to 36.7%); P=0.039; table J in appendix 2). The interaction analysis, with estimates for 1995 and 2015, showed a significant decrease in cure rates for albendazole from 38.6% (26.2% to 52.7%) to 16.4% (7.7% to 31.3%; P=0.027) and in egg reduction rates for albendazole from 72.6% (53.7% to 91.5%) to 43.4% (23.5% to 63.3%; P=0.049) and mebendazole from 91.4% (72.9% to 100.0%) to 54.7% (34.6% to 74.8%; P=0.014; table L in appendix 2).

Discussion
==========

Summary of key findings
-----------------------

Albendazole, the most widely used anthelmintic drug against *A lumbricoides* and hookworm, is highly effective, both in terms of cure rates and egg reduction rates. With about 134 million doses distributed in 2015, mebendazole is the second most widely used drug for infections with soil transmitted helminths.[@ref77] It has high efficacy against *A lumbricoides* and low activity against hookworm*.* Levamisole and pyrantel pamoate have high efficacy against *A lumbricoides*, and pyrantel pamoate has moderate efficacy against hookworm. The weakness of the currently available drugs is their low efficacy against *T trichiura,* for which mebendazole showed the best performance. This finding emphasises the urgent need for new drugs with higher efficacy against *T trichiura* for preventive chemotherapy programmes.[@ref10] [@ref11]

Our review provides up to date evidence on the efficacy of the four recommended anthelmintic drugs---albendazole, mebendazole, and the less widely used levamisole and pyrantel pamoate---based on a thorough review of the literature. For the first time a network-meta analysis was applied, and we meta-analysed summary estimates on egg reduction rates, a key parameter for efficacy of anthelmintic drugs.[@ref18]

Strength and limitations
------------------------

The main strength of our study was the innovative data analysis including the two measures of efficacy of anthelmintic drugs: cure rates and egg reduction rates. By applying a network meta-analysis, we could increase the evidence by including the efficacy results of a higher number of randomised controlled trials than in a previous meta-analysis.[@ref11] Furthermore, the model from Kessels and colleagues[@ref24] allowed the inclusion of studies with only one eligible treatment arm. To assess consistency of estimates, we compared odd ratios of cure from direct and indirect comparisons of the treatments with a plot (fig C in appendix 3). Although some of the differences were quite large, potentially challenging the validity of the indirect comparisons, none of the differences reached significance.

The reviewed randomised controlled trials cover the past 50 years of research. This inevitably leads to huge qualitative differences among the studies, which reflects the main challenge and limitation of our analyses. There were major disparities among the included studies, which affect drug efficacy---for instance, diagnostic method, infection intensity at baseline, statistical analyses, and sample size.

The diagnostic methods used in the reviewed studies ranged from lowest sensitivity methods, such as the direct smear, up to multiple Kato-Katz thick smears, which have a reasonable sensitivity. The sensitivity of diagnostic methods is associated with the infection intensity at baseline---for example, Kato-Katz has a reduced sensitivity for low egg counts.[@ref78] Both the diagnostic method and infection intensity at baseline directly influence cure rates and egg reduction rates.[@ref79] [@ref80] [@ref81] While the results stratified by infection intensities did not show a clear tendency for efficacy in this review, the sensitivity of the diagnostic method had an impact. Stratification of efficacy by low and moderate sensitivity of the diagnostic method significantly decreased cure rates of albendazole against *A lumbricoides* (P=0.044) and hookworm (P=0.023). We cannot, however, explain the increase in egg reduction rates with albendazole (P=0.024) against *T trichiura* (table E in appendix 2).

An additional limitation of the diagnostic methods (Kato-Katz, McMaster, etc) is their inability to distinguish between *A duodenale* and *N americanus*. Few included studies reported efficacies for specific hookworm species. The overall efficacies might differ according to the species. For example, while both hookworm species are somewhat susceptible to pyrantel pamoate, *N americanus* is reported to be less sensitive.[@ref82] The commonly higher abundance of *N americanus* in Africa than in Asia[@ref83] might have led to the borderline significant difference (P=0.053) in cure rates of pyrantel pamoate in Asia (64%) and Africa (27%; table C in appendix 2).

The network meta-analysis for egg reduction rates was limited by the lack of precision estimates in most of the studies and by the different choices of the measure of central tendency (arithmetic or geometric mean). There is an ongoing debate about advantages and disadvantages of the two systematically different means, while WHO now recommends the arithmetic mean.[@ref18] [@ref84] A few, mainly older, studies did not even report which measure of central tendency they used. In the absence of standard errors and confidence intervals, we could not optimise the precision of meta-analytic estimates. Moreover, as arithmetic and geometric means are systematically different, we had to adjust analyses of egg reduction rates for the type of mean.

To deal with potential publication bias, we compared results of smaller and larger studies in an interaction analysis. We might have slightly overestimated the effect of albendazole against hookworm, where the cure rate showed an almost significant negative association with study size (P=0.053). While the cure rates of *A lumbricoides* showed positive or stable associations with study size for all treatments, the rates of *T trichiura* after treatment with albendazole and mebendazole slightly decreased with increasing study size, yet not significantly. Thus, we did not find consistent evidence of publication bias (table J in appendix 2). The small number of available and eligible studies for levamisole is another limitation of our work. Consequently, all estimates relating to levamisole (cure rates, egg reduction rates, and odd ratios) have wide confidence intervals. Nonetheless, we present the first pooled estimates of efficacy for levamisole against hookworm, showing a low average cure rate (10.3%, with an upper 95% confidence limit of 35.2%), which conflicts with the fact that the drug is recommended for the treatment.[@ref3] [@ref11]

Clinical implications
---------------------

Efficacy of anthelmintic drugs is defined by cure rates and egg reduction rates. As both parameters have to be taken into consideration in comparisons of the efficacy of the drugs for each helminth species, the comparison was done qualitatively. Against *A lumbricoides* we found no significant differences, and all drugs had high efficacy. Albendazole had the highest efficacy for treating hookworm infections with significantly higher cure rates, followed by pyrantel pamoate, and lowest efficacy for levamisole and mebendazole when used at single oral doses. With regard to *T trichiura* infections, mebendazole had the highest, yet only moderate, efficacy, with significantly higher egg reduction rates than albendazole. The cure rates of levamisole and pyrantel pamoate did not differ from placebo.

Moreover, after stratification by year, we found a significant decrease in cure rates for albendazole against *T trichiura* (P=0.039) and a remarkable reduction against hookworm (table I in appendix 2). These results were even more pronounced in the interaction analysis. The cure rates for albendazole against *T trichiura* remained significantly lower (P=0.027). Furthermore, egg reduction rates of albendazole (p=0.027) against hookworm and of albendazole (P=0.049) and mebendazole (P=0.014) against *T trichiura* (table K in appendix 2) significantly decreased over time, which might be attributable to drug resistance.[@ref85] Several studies correlated reduced efficacies of benzimidazoles[@ref58] [@ref64] [@ref70] [@ref71] [@ref72] [@ref86] with emerging resistance. In 2015, more than a billion people infected with lymphatic filariasis and soil transmitted helminths were treated with albendazole,[@ref9] which is causing high drug pressure on parasites and might trigger drug resistance. In veterinary medicine, frequently repeated treatment with benzimidazoles has caused resistance in numerous nematode species.[@ref84] [@ref87] [@ref88] Resistance to anthelmintic drugs in humans, however, has not yet been shown. While the reduction in efficacy could be explained by emerging resistance, other factors, related to drug regimen, diagnostics, or host and parasite characteristics, might have contributed to the reduction.[@ref18] We evaluated the impact of some potential confounders but did not assess the influence of, for example, drug quality (original versus generic drugs), change in compliance over the years, or the day to day variation in egg excretion.[@ref18] [@ref89] Hence, future randomised controlled trials should follow a harmonised design to reduce confounders, as suggested by WHO,[@ref18] which will yield improved summary estimates of efficacy of anthelmintic drugs.

Conclusion
----------

Our data confirm that the most widely used drugs---albendazole and mebendazole---have shortcomings in their efficacy profile, especially against infections with hookworm and *T trichiura*. Alarmingly, the efficacy of albendazole and mebendazole has decreased over time. As the two most widely distributed drugs in preventive chemotherapy---albendazole and mebendazole---have been in use for almost 50 years, the threat of resistance is real and immediate. For careful monitoring of potential resistance, our summary estimates might help to revise current reference figures of efficacy.[@ref18]

There is an imminent need to strengthen efforts to develop new drugs for soil transmitted helminths. Alternatively, old and new drugs---such as tribendimidine, oxantel pamoate, moxidectin, or ivermectin---with different efficacy profiles could be used in combination with the recommended drugs to successfully tackle infections with all three soil transmitted helminths.[@ref12] [@ref90] Only with an integrated approach combining improved sanitation, health education,[@ref91] [@ref92] [@ref93] and scaling up of research for new anthelmintic drugs and use of drug combinations for preventive chemotherapy will we achieve the ultimate goal to control soil transmitted helminth infections. Furthermore, future randomised controlled trials should follow a harmonised design to reduce confounders and yield improved summary estimates of efficacy of anthelmintic drugs.

### What is already known on this topic

1.  The current strategy against soil transmitted helminths is preventive chemotherapy, mainly with albendazole, mebendazole, and, to a lesser extent, levamisole and pyrantel pamoate

2.  A previous meta-analysis presented summary estimates of cure rates of these drugs based on a small number of randomised controlled trials

### What this study adds

1.  The study provides up to date estimates of cure rates and egg reduction rates with network meta-analysis

2.  The two most commonly used drugs have shortcoming in their efficacy profile: mebendazole has low efficacy against hookworm and albendazole and mebendazole show low performance against *T trichiura*

3.  Efficacy albendazole and mebendazole against *T trichiura* has decreased over the past decades
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